Results 221 to 230 of about 205,233 (331)

Esketamine/Ketamine: Dual‐Action Mechanisms and Clinical Prospects beyond Anesthesia in Psychiatry, Immunology, and Oncology

Advanced Science, EarlyView.
Esketamine and ketamine are widely used for perioperative analgesia and anesthesia. Despite their established roles in analgesia, sedation, and anesthesia, as well as emerging antidepressant, anti‐tumor, and anti‐inflammatory effects, their clinical use is limited due to side effects and addiction potential.
Yinxin Wang, Jiangang Xu, Xinyu Zhou, Lu Che, Minghan Qiu, Yang Liu, Ming Gao, Zhen Yang   +7 more
wiley   +1 more source

Ligand and Residue Free Energy Perturbations Solve the Dual Binding Mode Proposal for an A_2BAR Partial Agonist. [PDF]

J Phys Chem B
Tandarić T, Gutiérrez-de-Terán H.
europepmc   +1 more source

Connexin43 Deficiency Leads to Ventricular Arrhythmias by Reprogramming Proline Metabolism

Advanced Science, EarlyView.
The study demonstrated that connexin43 (Cx43) knockout caused arrhythmic phenotype and decreased proline content in vitro and in vivo. Mechanistically, Cx43 interacts with the amino acid transporter SNAT2 (sodium‐dependent neutral amino acid transporter), and its deficiency disrupts proline transport and metabolism.
Hangying Ying, Hangping Fan, Yunhe Wang, Ruhong Jiang, Dongsheng Cai, Hui Cheng, Hao Wang, Chenyang Jiang, Ping Liang   +8 more
wiley   +1 more source

Anti-Inflammatory and Antinociceptive Properties of the Quercetin-3-Oleate AV2, a Novel FFAR1 Partial Agonist. [PDF]

Int J Mol Sci
Pessina F, Casini I, Gamberucci A, Carullo G, Signorini C, Brizzi A, Aiello F, Aloisi AM, Pieretti S.   +8 more
europepmc   +1 more source

Insights into the molecular mechanism of positive cooperativity between partial agonist MK-8666 and full allosteric agonist AP8 of hGPR40 by Gaussian accelerated molecular dynamics (GaMD) simulations. [PDF]

Comput Struct Biotechnol J, 2021
An X, Bai Q, Bing Z, Liu H, Yao X.
europepmc   +1 more source

Augmentation therapy with serotonin1A receptor partial agonists on neurocognitive function in schizophrenia: A systematic review and meta-analysis

, 2023
Risa Yamada, Ayumu Wada, Andrew Stickley, Yuma Yokoi, Tomiki Sumiyoshi   +4 more
openalex   +1 more source

Crossing the Blood–Brain Barrier with Molecularly Imprinted Polymeric Nanocarriers: An Emerging Frontier in Brain Disease Therapy

Advanced Science, EarlyView.
Molecularly imprinted polymeric nanocarriers (nanoMIPs) offer robust, antibody‐mimetic platforms to overcome the blood‐brain barrier. The article surveys nanoMIP design and ligand‐directed surface engineering that harness receptor‐mediated transcytosis, and highlights therapeutic and diagnostic applications in neurodegeneration, brain tumors and ...
Ranjit De, Shuliang Shi, Kyong‐Tai Kim
wiley   +1 more source

Selective dopamine D3 receptor partial agonist (±)VK4-40 reduces the reinforcing strength of d-amphetamine but not cocaine in rhesus monkeys responding under a progressive-ratio schedule of reinforcement. [PDF]

Drug Alcohol Depend
Allen MI, Lewis EA, Cao J, Newman AH, Nader MA.   +4 more
europepmc   +1 more source

Vitamin D is an endogenous partial agonist of the transient receptor potential vanilloid 1 channel. [PDF]

J Physiol, 2020
Long W, Fatehi M, Soni S, Panigrahi R, Philippaert K, Yu Y, Kelly R, Boonen B, Barr A, Golec D, Campbell SA, Ondrusova K, Hubert M, Baldwin T, Lemieux MJ, Light PE.   +15 more
europepmc   +1 more source

Carteolol is a partial agonist on β2-adrenoceptors and atypical 0-adrenoceptors in guinea pig gastrointestine

, 2000
Takahiro Horinouchi, Michihiko Tsujitani, Katsuo Koike   +2 more
openalex   +1 more source